Working… Menu

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04475731
Recruitment Status : Not yet recruiting
First Posted : July 17, 2020
Last Update Posted : January 5, 2021
Information provided by (Responsible Party):
Gruppo Italiano Malattie EMatologiche dell'Adulto

Brief Summary:
This is a phase II interventional trial to evaluate if the use of ponatinib, with or without chemotherapy, can induce a molecular remission in MRD-positive patients, in patients in hematologic and extra-hematologic relapse and in the few patients who never achieved an hematologic remission after whatever prior treatment.

Condition or disease Intervention/treatment Phase
Philadelphia-Positive ALL Acute Lymphoblastic Leukemia, in Relapse Drug: Ponatinib Phase 2

Detailed Description:

This is a phase II interventional multicenter study for adult patients with Ph+ALL who:

  • Are MRD+ (i.e. BCR-ABL1/ABL1 >0.01) (or loose their molecular response) after whichever kind of previous treatment. MRD positivity is indeed regarded as a relapse/resistance, since it represents the early recognition of cases who will eventually experience an hematologic recurrence of disease.
  • Are in hematologic relapse after whichever kind of previous treatment.
  • Have never achieved an hematologic remission at least after one month of treatment.

Patients will be treated with Ponatinib at a dose of 45 mg/die per os for 28 days for 3 cycles and - if in hematologic and extra-hematologic relapse/refractoriness, clinically fit and according to medical decision - with concurrent systemic chemotherapy. In case of CMR achievement, dosing will be reduced to 30 mg. In case of toxicity, Ponatinib will be reduced to 30 (or 15) mg daily.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 67 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Ponatinib for the Management of Minimal Residual Disease (MRD) and Hematologic Relapse in Adult Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL) Patients
Estimated Study Start Date : February 2021
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : November 2024

Arm Intervention/treatment
Experimental: Experimental arm

MRD+ Ph+ ALL adult patients will receive Ponatinib x 4 weeks x 3 courses; +/-Concomitant chemotherapy (according to hematologic status).

Patients will receive the study drug until disease relapse or progression.

Drug: Ponatinib

Ponatinib 45 mg/day x 4 weeks x 3 courses.

+/- chemotherapy:

  • vincristine or
  • L-VAMP (leucovorin, vincristine, aracytin, methotrexate, prednisone)

Primary Outcome Measures :
  1. MRD negativity/reduction rate [ Time Frame: After 3 months of treatment ]
    Rate of patients who achieve a MRD negativity/MRD reduction following treatment with either Ponatinib alone or in combination with systemic chemotherapy

Secondary Outcome Measures :
  1. Duration of CMR [ Time Frame: at 24 months ]
    Duration of the CMR status after 3 months of ponatinib treatment

  2. Hematologic remission rate [ Time Frame: at 24 months ]
    The achievement of an hematologic remission in patients treated for an hematologic and extra-hematoloigc relapse and for a refractory disease.

  3. Best molecular response [ Time Frame: at 24 months ]
    Best molecular response achieved during the follow-up

  4. Rate of AE/SAEs [ Time Frame: at 24 months ]
    Safety profile in terms of incidence of grade >3 CTC-NCI side effects and toxicities (AE/SAEs).

  5. Mutational analysis [ Time Frame: at 24 months ]
    Mutational analysis in terms of occurrence, type and number of BCR-ABL1 kinase domain mutations.

  6. Correlation between biological and MRD parameters [ Time Frame: at 24 months ]
    Correlation between the achievement and duration of CMR (or MRD reduction) with the type of fusion protein (e.g. p190 or p210) and the potential occurrence of mutations, as well as with additional genomic lesions.

  7. Disease free survival [ Time Frame: 24 months ]
    Time interval between the achievement of CHR after three months of ponatinib and hematologic relapse of the disease or death in CHR; patients still alive, in CHR.

  8. Overall survival [ Time Frame: 24 months ]
    Time interval between treatment start and death for any cause.

  9. Cumulative incidence of relapse [ Time Frame: 24 months ]
    Time interval between achievement of CHR after three months of ponatinib until the date of first hematologic relapse of the disease.

  10. Role of hematological profile on survival outcome [ Time Frame: at 24 months ]
    Identification of hematological profile on survival outcome

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Ph+ ALL patients with evidence of MRD disease or in hematologic and extra-hematologic relapse/refractoriness after any previous treatment, will be considered eligible to enter the study.
  2. Age ≥18 years old with no upper age limit.
  3. Adequate hepatic function as defined by the following criteria:

    • total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome
    • alanine aminotransferase (ALT) ≤2.5 × ULN
    • aspartate aminotransferase (AST) ≤2.5 × ULN.
  4. Adequate pancreatic function as defined by the following criterion:

    - serum lipase and amylase ≤1.5 × ULN.

  5. For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment.
  6. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 4 months after the end of treatment.
  7. Signed written informed consent according to ICH/EU/GCP and national local laws.

Exclusion Criteria:

  1. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).
  2. Uncontrolled active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubine ≥ 1.5 x ULN not due to the disease.
  3. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis.
  4. History of alcohol abuse.
  5. Ongoing or active uncontrolled infections.
  6. Uncontrolled hypertriglyceridemia (triglycerides >450 mg/dL).
  7. Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to:

    • any history of myocardial infarction, stroke, or revascularization
    • unstable angina or transient ischemic attack within 6 months prior to enrollment
    • congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards within 6 months prior to enrollment
    • history of clinically significant (as determined by the treating physician) atrial arrhythmia
    • any history of ventricular arrhythmia
    • any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism
    • uncontrolled hypertension (diastolic blood pressure >90 mm Hg; systolic >140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.
  8. Taking medications that are known to be associated with Torsades de Pointes.
  9. Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib.
  10. Creatinine level >2.5mg/dl or glomerular filtration rate (GFR) <20 ml/min or proteinuria >3.5 g/day.
  11. Patients who are currently receiving treatment with any of the medications listed in Appendix E if the medications cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04475731

Layout table for location contacts
Contact: Paola Fazi 0670390528
Contact: Enrico Crea 0670390514

Sponsors and Collaborators
Gruppo Italiano Malattie EMatologiche dell'Adulto
Layout table for additonal information
Responsible Party: Gruppo Italiano Malattie EMatologiche dell'Adulto Identifier: NCT04475731    
Other Study ID Numbers: ALL2620
First Posted: July 17, 2020    Key Record Dates
Last Update Posted: January 5, 2021
Last Verified: June 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action